Solara Active Pharma Sciences · NSE: SOLARA · BSE: 541540
Q1 FY21 results · Apr–Jun 2020
Solara Active Pharma Sciences reported revenue from operations of ₹348.42 crore (up 5.5% from Q1 FY20) and net profit of ₹42.27 crore (up 59.5% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 348.42 | 330.17 | +5.5% | 296.77 | +17.4% |
| Other income | 4.58 | 4.36 | +5.0% | 12.13 | −62.2% |
| Total income | 353.00 | 334.53 | +5.5% | 308.90 | +14.3% |
| Profit before tax | 42.32 | 26.50 | +59.7% | 17.90 | +136.4% |
| Net profit for the period | 42.27 | 26.50 | +59.5% | 17.81 | +137.3% |
| Attributable to shareholders of the company | 42.28 | 26.52 | +59.4% | 14.26 | +196.5% |
| EPS, basic (₹) | 15.74 | 10.29 | +53.0% | 6.78 | +132.1% |
| Net margin (%) | 12.1 | 8.0 | 6.0 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 348.42 | 314.09 | +10.9% | 296.77 | +17.4% |
| Other income | 4.58 | 2.97 | +54.2% | 12.11 | −62.2% |
| Total income | 353.00 | 317.06 | +11.3% | 308.88 | +14.3% |
| Profit before tax | 42.09 | 25.32 | +66.2% | 18.18 | +131.5% |
| Net profit for the period | 42.09 | 25.32 | +66.2% | 18.18 | +131.5% |
| EPS, basic (₹) | 15.67 | 9.82 | +59.6% | 6.92 | +126.6% |
| Net margin (%) | 12.1 | 8.1 | 6.1 |
Consolidated
- Filed with BSE
- 08 Aug 2020, 14:04 IST
- Board meeting
- 03 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 08 Aug 2020, 14:04 IST
- Board meeting
- 03 Aug 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE